At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
Onabotulinumtoxin A +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized Study to Compare Onabotulinumtoxin A Versus Kenalog for Intravaginal Trigger Point Injections in the Treatment of Chronic Pelvic Pain
In Brief
A clinical study evaluating Onabotulinumtoxin A and Kenalog for Pelvic Pain. Completed, enrolled 21 participants across 1 site.
Detailed Summary
The goal of this study is to compare the effectiveness of two different medications used in intravaginal trigger point injections (injections into extremely painful areas of a muscle) to treat chronic pelvic pain. The study compares onabotulinumtoxinA (BOTOX®) (a drug prepared from the bacterial toxin botulin which temporarily paralyzes muscles) to Kenalog (a synthetic corticosteroid used as an anti-inflammatory agent).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPelvic Pain
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartAug 2015
Primary CompletionMar 2018
Study CompletionSep 2018
TodayJul 2026
First PostedFeb 23, 2015
Enrollment StartAug 1, 2015
Primary CompletionMar 26, 2018
Study CompletionSep 24, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 11.4 years ago
Interventions
Onabotulinumtoxin Adrug
Intravaginal pelvic floor injection one series
Kenalogdrug
Intravaginal pelvic floor injection one series